Stada on the prowl for new deals

Germany's Stada Arzneimittel says it's checking out potential takeover targets, looking to continue its recent series of acquisitions, Forbes reports. The generics maker said it may have to raise new capital for the deals so it can maintain its equity ratios.

Stada has been expanding in eastern Europe through takeovers to combat a shrinking generics market at home in Germany. Among its buys: Hemofarm of Serbia, which it bought for $780 million, and Russia's Makiz. Still, the company isn't doing badly at home: Its domestic market lost 3 percent overall last year, but Stada managed to grow its own domestic sales by 20 percent. On the whole, its sales rose by 26 percent to $2.48 billion.

- check out the Forbes coverage

Related Articles:
Stada sells off U.S. sub, exits market. Report
Stada buys Russian pharma group. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.